Study guide
3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT)
CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Exam Overview
1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide
2 Chapter 2: Cancer & Cancer Treatment Modalities
2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)
3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging
3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors
4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy
4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome
5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination
5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes
6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety
6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology
7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics
7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics
3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT)
Key Takeaways Explain This Topic AI
Unintentional weight loss percentage calculation formula ( [ ( Usual Wt − Current Wt ) / Usual Wt ] × 100 [ (\text{Usual Wt} - \text{Current Wt}) / \text{Usual Wt} ] \times 100 [( Usual Wt − Current Wt ) / Usual Wt ] × 100 ) evaluates velocity of loss; severe thresholds are >2% in 1 week, >5% in 1 month, >7.5% in 3 months, and >10% in 6 months.
Fluid retention (edema, pleural effusion, ascites) artificially inflates scale weight; dry body weight is estimated by deducting 1–2 kg for mild edema, 5–7 kg for moderate edema, and 10–15+ kg for severe edema/ascites.
Sarcopenic obesity (high body fat masking severe muscle depletion) alters hydrophilic chemotherapy distribution volume, leading to severe grade 3–4 toxicity when dosing is calculated using total Body Surface Area (BSA).
Opportunistic L3 Computed Tomography (CT) scan analysis is the gold standard for measuring Skeletal Muscle Index (SMI in cm²/m²); diagnostic sarcopenia cutoffs are <55 cm²/m² for men and <39 cm²/m² for women (<41 cm²/m² in female obesity).
Bioelectrical Impedance Analysis (BIA) Phase Angle (<4.5°–5.0°) and Handgrip Dynamometry (<27 kg men, <16 kg women) provide essential objective measures of cellular membrane integrity and functional muscle strength.
Last updated: August 2026
Anthropometrics & Body Composition Analysis (DEXA, BIA, CT)
Accurate interpretation of anthropometric and body composition data in oncology requires looking far beyond total scale weight. Fluid accumulation, tumor mass, and altered muscle-to-fat ratios frequently obscure severe muscle depletion. Specialized body composition analysis and functional strength testing are critical diagnostic tools for the Board Certified Specialist in Oncology Nutrition (CSO).
Unintentional Weight Loss Calculations & Timeframes
Percentage of unintentional weight loss evaluates the velocity and severity of tissue loss: % Weight Loss = ( Usual Body Weight − Current Body Weight Usual Body Weight ) × 100 \text{\% Weight Loss} = \left( \frac{\text{Usual Body Weight} - \text{Current Body Weight}}{\text{Usual Body Weight}} \right) \times 100 % Weight Loss = ( Usual Body Weight Usual Body Weight − Current Body Weight ) × 100
Clinical severity is classified based on time elapsed:
- Time Frame Significant Weight Loss (%) Severe Weight Loss (%)
- 1 Week 1 − 2 % 1 - 2\% 1 − 2% > 2 % > 2\% > 2%
- 1 Month 5 % 5\% 5% > 5 % > 5\% > 5%
- 3 Months 7.5 % 7.5\% 7.5% > 7.5 % > 7.5\% > 7.5%
- 6 Months 10 % 10\% 10% > 10 % > 10\% > 10%
- 1 Year 20 % 20\% 20% > 20 % > 20\% > 20%
- Adjusting for Fluid Retention (Edema & Ascites)
Fluid accumulation (pedal edema, sacral edema, pleural effusion, ascites) artificially inflates scale weight and masks tissue wasting. Clinicians must estimate dry body weight by subtracting estimated fluid weight:
Peripheral Edema Deductions:
Mild ( 1 + 1+ 1 + pitting, ankle): Deduct ∼ 1 − 2 kg \sim 1 - 2\text{ kg} ∼ 1 − 2 kg ( ∼ 5 % \sim 5\% ∼ 5% body weight).
Moderate ( 2 − 3 + 2 - 3+ 2 − 3 + pitting, to knee): Deduct ∼ 5 − 7 kg \sim 5 - 7\text{ kg} ∼ 5 − 7 kg ( ∼ 10 % \sim 10\% ∼ 10% body weight).
Severe ( 4 + 4+ 4 + pitting / Anasarca): Deduct ∼ 10 − 15 + kg \sim 10 - 15+\text{ kg} ∼ 10 − 15 + kg ( ≥ 15 % \ge 15\% ≥ 15% body weight).
Ascites Deductions:
Mild Ascites: Deduct ∼ 3 − 5 kg \sim 3 - 5\text{ kg} ∼ 3 − 5 kg .
Moderate Ascites: Deduct ∼ 7 − 10 kg \sim 7 - 10\text{ kg} ∼ 7 − 10 kg .
Severe / Tense Ascites: Deduct ∼ 12 − 15 + kg \sim 12 - 15+\text{ kg} ∼ 12 − 15 + kg .
Sarcopenic Obesity in Oncology
Sarcopenic Obesity is defined as the co-occurrence of high adiposity (BMI ≥ 30 kg/m 2 \ge 30\text{ kg/m}^2 ≥ 30 kg/m 2 ) and severe skeletal muscle depletion. It is particularly prevalent in breast, prostate, colorectal, and pancreatic cancer patients receiving adjuvant chemotherapy or hormonal therapies.
Pharmacokinetic & Clinical Implications
Chemotherapy Toxicity: Systemic chemotherapy dosing is historically calculated using Body Surface Area (BSA), calculated via the Mosteller formula: BSA (m 2 ) = Height (cm) × Weight (kg) 3600 \text{BSA (m}^2\text{)} = \sqrt{\frac{\text{Height (cm)} \times \text{Weight (kg)}}{3600}} BSA (m 2 ) = 3600 Height (cm) × Weight (kg)
In sarcopenic obesity, high body weight inflates BSA, yielding a higher absolute chemotherapy dose. However, hydrophilic chemotherapeutic agents (e.g., 5-fluorouracil, carboplatin, cisplatin, doxorubicin) distribute primarily into lean muscle mass. Because lean muscle mass is severely contracted, drug concentration per unit of muscle mass becomes excessively high, triggering severe grade 3–4 hematologic and gastrointestinal toxicities, forced dose reductions, and premature treatment discontinuation.
Prognostic Impact: Sarcopenic obese patients suffer higher surgical complication rates, longer hospitalizations, and significantly reduced overall survival compared to non-sarcopenic obese controls.
Advanced Body Composition Assessment Modalities +-----------------------------------------------------------------------+
- | BODY COMPOSITION MODALITIES IN ONCOLOGY |
- +-----------------------------------------------------------------------+
- | 1. COMPUTED TOMOGRAPHY (CT) AT L3 (Gold Standard) |
- | - Measures: Cross-sectional Skeletal Muscle Area (SMA in cm²) |
- | - Normalizes for height: Skeletal Muscle Index (SMI = SMA / m²) |
- | - Sarcopenia Cutoffs: < 55 cm²/m² (Men), < 39 cm²/m² (Women) |
- | 2. BIOELECTRICAL IMPEDANCE ANALYSIS (BIA) |
- | - Measures: Resistance (R) & Reactance (Xc) to electrical current |
- | - Derives: Phase Angle = arctan(Xc / R) x (180 / pi) |
- | - Prognostic Cutoff: Phase Angle < 4.5° to 5.0° indicates cell |
- | membrane breakdown and shortened overall survival |
- | 3. DUAL-ENERGY X-RAY ABSORPTIOMETRY (DEXA) |
- | - Measures: Appendicular Lean Mass (ALM) |
- | - Cutoffs: ALM Index < 7.0 kg/m² (Men), < 5.5 kg/m² (Women) |
- | 4. HANDGRIP DYNAMOMETRY (Functional Strength) |
- | - EWGSOP2 Cutoffs: Handgrip < 27 kg (Men), < 16 kg (Women) |
- +-----------------------------------------------------------------------+
- 1. Computed Tomography (CT) Scans at L3 (Gold Standard)
Opportunistic Secondary Analysis: Utilizes routine diagnostic oncology CT imaging at the 3rd lumbar vertebra (L3) level.
Tissue Segmentation: Software segments tissues based on Hounsfield Unit (HU) radiodensity thresholds: Skeletal muscle ( − 29 to + 150 HU -29\text{ to } +150\text{ HU} − 29 to + 150 HU ), Visceral adipose tissue ( − 150 to − 50 HU -150\text{ to } -50\text{ HU} − 150 to − 50 HU ), Subcutaneous adipose tissue ( − 190 to − 30 HU -190\text{ to } -30\text{ HU} − 190 to − 30 HU ).
Skeletal Muscle Index (SMI): SMI (cm 2 /m 2 ) = Skeletal Muscle Area (cm 2 ) / [ Height (m) ] 2 \text{SMI (cm}^2\text{/m}^2\text{)} = \text{Skeletal Muscle Area (cm}^2\text{)} / [\text{Height (m)}]^2 SMI (cm 2 /m 2 ) = Skeletal Muscle Area (cm 2 ) / [ Height (m) ] 2 .
Diagnostic Cutoffs for Sarcopenia (Martin et al.):
Men: SMI < 55 cm 2 /m 2 \text{SMI } < 55\text{ cm}^2\text{/m}^2 SMI < 55 cm 2 /m 2 (if BMI ≥ 25 \ge 25 ≥ 25 ) or < 43 cm 2 /m 2 < 43\text{ cm}^2\text{/m}^2 < 43 cm 2 /m 2 (if BMI < 25 < 25 < 25 ).
Women: SMI < 39 cm 2 /m 2 \text{SMI } < 39\text{ cm}^2\text{/m}^2 SMI < 39 cm 2 /m 2 ( < 41 cm 2 /m 2 < 41\text{ cm}^2\text{/m}^2 < 41 cm 2 /m 2 in female obesity).
2. Bioelectrical Impedance Analysis (BIA) & Phase Angle
Mechanism: Measures electrical impedance—comprising resistance ( R R R , opposition to current flow through body water) and reactance ( X c Xc X c , capacitive storage by cell membranes)—as low-frequency alternating current passes through tissues.
Phase Angle (PA): Derived via the mathematical relationship: PA (degrees) = arctan ( X c / R ) × ( 180 / π ) \text{PA (degrees)} = \arctan(Xc / R) \times (180 / \pi) PA (degrees) = arctan ( X c / R ) × ( 180/ π ) .
Clinical Significance: Reflects cell membrane capacitance and cellular integrity. Normal PA is 5.0 ∘ − 7.0 ∘ 5.0^\circ - 7.0^\circ 5. 0 ∘ − 7. 0 ∘ . A Phase Angle < 4.5 ∘ to 5.0 ∘ <4.5^\circ \text{ to } 5.0^\circ < 4. 5 ∘ to 5. 0 ∘ indicates breakdown of cell membrane structure, fluid shift from intracellular to extracellular space, severe cellular exhaustion, and serves as an independent predictor of mortality in cancer.
3. Functional Muscle Strength: Handgrip Dynamometry
Procedure: Measures isometric handgrip strength using a calibrated hydraulic dynamometer (best of 3 trials per hand).
EWGSOP2 Diagnostic Sarcopenia Cutoffs:
- Men: < 27 kg < 27\text{ kg} < 27 kg
- Women: < 16 kg < 16\text{ kg} < 16 kg
- Detailed Worked Clinical Case Study
- Patient Scenario
A 68-year-old male with metastatic colorectal cancer presents for body composition assessment prior to starting palliative chemotherapy. Scale weight = 84 kg 84\text{ kg} 84 kg , Height = 178 cm 178\text{ cm} 178 cm (Scale BMI = 26.5 kg/m 2 26.5\text{ kg/m}^2 26.5 kg/m 2 ). Usual weight 4 months ago was 95 kg 95\text{ kg} 95 kg . Physical exam shows 3 + 3+ 3 + pedal edema and moderate abdominal ascites.
Step-by-Step Assessment
Fluid Adjustment & True Dry Weight:
3 + 3+ 3 + pedal edema → \rightarrow → Deduct ∼ 6 kg \sim 6\text{ kg} ∼ 6 kg .
Moderate ascites → \rightarrow → Deduct ∼ 8 kg \sim 8\text{ kg} ∼ 8 kg .
Total fluid deduction = 14 kg 14\text{ kg} 14 kg .
True Dry Weight: 84 − 14 = 70 kg 84 - 14 = 70\text{ kg} 84 − 14 = 70 kg .
Percentage Weight Loss Calculation:
[ ( 95 − 70 ) / 95 ] × 100 = ( 25 / 95 ) × 100 = 26.3 % [(95 - 70) / 95] \times 100 = (25 / 95) \times 100 = 26.3\% [( 95 − 70 ) /95 ] × 100 = ( 25/95 ) × 100 = 26.3% unintentional weight loss over 4 months.
Interpretation: Severe Weight Loss ( > 7.5 % >7.5\% > 7.5% in 3 months / > 10 % >10\% > 10% in 6 months).
Dry BMI Calculation:
Dry BMI = 70 / ( 1.78 ) 2 = 22.1 kg/m 2 \text{Dry BMI} = 70 / (1.78)^2 = 22.1\text{ kg/m}^2 Dry BMI = 70/ ( 1.78 ) 2 = 22.1 kg/m 2 .
CT L3 Scan & BIA Evaluation:
CT L3 Skeletal Muscle Index = 42 cm 2 / m 2 42\text{ cm}^2/\text{m}^2 42 cm 2 / m 2 ( < 55 cm 2 / m 2 <55\text{ cm}^2/\text{m}^2 < 55 cm 2 / m 2 cutoff → \rightarrow → Severe Sarcopenia ).
BIA Phase Angle = 4.1 ∘ 4.1^\circ 4. 1 ∘ ( < 4.5 ∘ <4.5^\circ < 4. 5 ∘ cutoff → \rightarrow → High Risk of Cellular Membrane Breakdown & Shortened Survival ).
Handgrip Strength = 21 kg 21\text{ kg} 21 kg ( < 27 kg <27\text{ kg} < 27 kg cutoff → \rightarrow → Low Muscle Strength ).
Comprehensive Clinical Synthesis
Despite a scale BMI of 26.5 kg/m 2 26.5\text{ kg/m}^2 26.5 kg/m 2 suggesting overweight status, fluid-adjusted analysis reveals 26.3 % 26.3\% 26.3% severe weight loss, severe sarcopenia, cellular membrane failure, and reduced muscle strength.